Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

This study is evaluating naxitamab (hu3F8), an antibody treatment, in children with high-risk or relapsed/refractory neuroblastoma (a type of cancer that primarily affects young children and forms in nerve tissue). Naxitamab targets a protein called GD2 found on neuroblastoma cells. **You may be eligible if...** - You (or your child) are at least 1 year old - You have a confirmed diagnosis of high-risk neuroblastoma, or neuroblastoma that has come back or isn't responding to treatment - You (or your child's guardian) can provide written consent - You are using effective contraception if sexually active **You may NOT be eligible if...** - You have significant toxicity to vital organs - You have a known allergy to anti-GD2 antibodies or GM-CSF - You are pregnant, planning to become pregnant, or breastfeeding - You are currently taking another experimental drug or within 4 weeks of having done so - You are already enrolled in an active Y-mAbs sponsored naxitamab trial - Your heart function is below 50% (ejection fraction) Talk to your doctor to see if this trial is right for you.